Core Insights - Verano Holdings Corp. reported its financial results for Q1 2025, showing a decrease in revenues and gross profit compared to previous quarters, primarily due to increased promotional activity and price compression in key markets [1][5][6] Financial Performance - Revenues for Q1 2025 were $210 million, down 5% year-over-year from $221 million in Q1 2024 and down 4% from $218 million in Q4 2024 [5][8] - Gross profit for Q1 2025 was $100 million, representing 47% of revenue, a decline from 51% in Q1 2024 and 49% in Q4 2024 [6][8] - The company reported a net loss of $12 million, or 5% of revenue, compared to a net loss of $5 million, or 2% of revenue, in Q1 2024 [10][8] - Adjusted EBITDA for Q1 2025 was $54 million, or 26% of revenue, down from $66 million, or 30% of revenue, in Q1 2024 [10][31] Operational Highlights - The company expanded its retail footprint by opening new dispensaries, bringing its total to 81 in Florida and 155 across 13 states [15] - Verano launched new products in response to market demand, including innovative vapes and pre-roll joints [15] - The company secured an additional $12 million in financing by leveraging its owned CPG real estate in Nevada and Arizona [15] Management Commentary - The CEO expressed satisfaction with the company's progress in executing strategic priorities, emphasizing innovation, automation, and operational efficiencies [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Canopy Growth Corporation regarding a class action lawsuit due to alleged misleading statements and undisclosed costs impacting the company's financial performance [1]. Group 1: Allegations - The complaint alleges that Canopy Growth Corporation incurred significant costs related to the production of Claybourne pre-rolled joints during its product launch in Canada [1]. - It is claimed that these costs, along with indirect costs from Storz & Bickel vaporizer devices, negatively affected the company's gross margins and overall financial results [1]. - The defendants are accused of overstating the effectiveness of Canopy's cost reduction measures and downplaying issues related to gross margins, leading to materially false and misleading public statements [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as May 30, 2024, to February 6, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Tilray Brands is currently trading at its all-time low, having lost 94% of its value over the past five years, primarily due to the lack of marijuana legalization in the U.S. which investors had anticipated [1][4][10] Financial Performance - The company's total net revenue for the most recent quarter ended on February 28 was $185.8 million, reflecting a 1% decline [7] - Tilray reported an operating loss of $760 million, which included impairment charges of nearly $700 million [7] - The company burned through $5.8 million in cash from its day-to-day operations [7] Growth Strategy - Tilray has been pivoting towards alcohol to grow its top line, but this strategy has not generated sufficient growth to attract investors [5][6] - The company is exploring international cannabis markets and acquiring craft beer brands in the U.S. as potential growth avenues, but these efforts have not yielded significant results [6] Investment Considerations - The stock has been in a continuous decline, and buying it at a lower price has not proven to be a successful strategy [9] - Without a significant catalyst for growth or a clear path to profitability, the stock may not be a worthwhile investment at this time [10]

Core Viewpoint - Rubicon Organics Inc. has successfully closed a non-brokered private placement offering, raising approximately $4.5 million through the issuance of 10,227,265 units at a price of $0.44 per unit [1][2]. Group 1: Offering Details - Each unit consists of one common share and one-half of a common share purchase warrant, with warrants priced at $0.70 and valid for 24 months [2]. - The company paid finders' fees totaling approximately $100,467 and issued 228,335 finder warrants, also exercisable at $0.70 for 24 months [3]. - All units issued are not subject to a hold period under Canadian securities laws due to the exemption utilized [4]. Group 2: Board Participation - Members of the Board subscribed for a total of 3,410,545 units, generating approximately $1.5 million in gross proceeds [5]. - The participation of Board members is classified as a related party transaction, with the company relying on exemptions from formal valuation and minority shareholder approval requirements [5]. Group 3: Use of Proceeds - The net proceeds from the offering will be allocated for start-up and acquisition costs of the Hope Facility, pre-roll automation, capital investments, and general working capital [6]. - If the acquisition of the Hope Facility does not proceed, the funds may be redirected to other projects or working capital needs [6]. Group 4: Ownership Changes - Following the offering, Jesse McConnell's ownership increased from 21.13% to approximately 18.65% of the undiluted common shares outstanding [8][9]. - McConnell's total holdings now include 12,745,118 common shares, 325,000 stock options, 450,000 restricted share units, 140,459 deferred share units, and 250,000 warrants [9]. Group 5: Company Overview - Rubicon Organics Inc. is a leader in premium organic cannabis products, vertically integrated through its subsidiary Rubicon Holdings Corp [12]. - The company focuses on profitability through its premium cannabis flower and brand management, featuring brands like Simply Bare™ Organic and Wildflower™ [12][13].

Core Viewpoint - MariMed Inc. reported its financial results for Q1 2025, highlighting revenue growth driven by wholesale sales despite challenges in retail performance [1][2]. Financial Performance - Revenue for Q1 2025 was $38.0 million, a slight increase from $37.9 million in Q1 2024 [3]. - GAAP gross margin decreased to 40% from 43% year-over-year, while non-GAAP gross margin fell to 41% from 44% [3]. - The company reported a GAAP net loss of $5.4 million compared to a loss of $1.3 million in the same quarter last year [3]. - Non-GAAP adjusted EBITDA was $2.6 million, down from $4.7 million in Q1 2024, with a margin of 7% compared to 12% [3]. Operational Highlights - MariMed expanded its market presence by selling products into 70 new storefronts, with wholesale sales now accounting for 44% of total revenue [2]. - The company completed the acquisition of First State Compassion Center, enhancing its operational capabilities in Delaware [5][6]. - New product launches included the distribution of Nature's Heritage™ cannabis products in Illinois and the introduction of a new caramel chew under the Betty's Eddies™ brand [11]. Management Commentary - The CEO emphasized the company's commitment to building a leading consumer packaged goods company in the cannabis sector, focusing on brand distribution and operational efficiencies [2]. - The CFO noted that wholesale sales helped mitigate the impact of a weaker retail quarter and highlighted ongoing efforts to manage costs and explore new revenue streams [2]. Revenue Breakdown - Retail product sales were $20.8 million, down from $22.3 million in Q1 2024, while wholesale product sales increased to $16.8 million from $14.5 million [27]. - Other revenue sources contributed $0.4 million, down from $1.1 million in the previous year [27]. Balance Sheet Overview - As of March 31, 2025, total assets were $208.0 million, slightly up from $206.9 million at the end of 2024 [19][20]. - Current liabilities increased to $55.3 million from $48.7 million, reflecting higher accrued expenses and income taxes payable [20]. - Stockholders' equity decreased to $59.2 million from $59.9 million, primarily due to the net loss reported [20]. Future Outlook - The company plans to continue expanding its brand distribution and explore mergers and acquisitions as part of its growth strategy [2]. - Management remains focused on disciplined cost management and operational efficiencies to enhance shareholder value [2].

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation (NASDAQ: CGC). Shareholders who purchased shares of CGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/canopy-growth-corporation-loss-submission-form-2/?id=147121&from=3 CLASS PE ...

LAS VEGAS, May 07, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, announced today that it plans to release its financial results for the first quarter ended March 31st, 2025, on May 14th, 2025, aftermarket.Planet 13 will host a conference call on May 14th, 2025, to discuss its first quarter financial results and provide investors with key business highlights, strategy, and outlook. The c ...

Core Viewpoint - A class action securities lawsuit has been filed against Canopy Growth Corporation, alleging securities fraud that negatively impacted investors between May 30, 2024, and February 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Canopy Growth Corporation made false statements regarding the costs associated with the production of Claybourne pre-rolled joints and Storz & Bickel vaporizer devices, which were likely to adversely affect the company's gross margins and overall financial results [2]. - It is alleged that the defendants overstated the effectiveness of Canopy's cost reduction measures and the health of its gross margins while downplaying related issues, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Insights - The marijuana sector continues to face significant challenges, leading to a lack of investor interest, particularly as cannabis remains illegal at the federal level in the U.S. [1] - Tilray Brands has experienced a substantial decline in its stock value, losing over 26% in April and trading under $1, indicating a prolonged downward trend [1][4] - The company reported a 1% year-over-year decline in net revenue for fiscal Q3 2025, totaling just under $186 million, and posted a non-GAAP loss of $2.9 million compared to a profit of $885,000 in the same period the previous year [2][4] Financial Performance - Tilray's management has reduced its revenue guidance for 2025, now expecting $850 million to $900 million, down from a previous estimate of $950 million to $1 billion [4] - The company is considering a reverse stock split with a proposed ratio of 1-to-10 to 1-to-20 to boost its stock price, which will be voted on in a special shareholders' meeting on June 10 [5] Diversification Efforts - In an attempt to diversify, Tilray has been acquiring craft breweries, as beer has broader market appeal and is not subject to the same regulatory challenges as cannabis [7] - However, the beer market has also faced challenges, with consumption hitting a four-decade low in 2024, raising doubts about whether this strategy will improve Tilray's fortunes [8] Market Outlook - There are currently no clear catalysts for Tilray's recovery, with the only potential being the decriminalization of cannabis in the U.S., which appears unlikely in the near term [9]

BOCA RATON, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the first quarter ended March 31, 2025, after the market closes on Thursday, May 8, 2025. Management has updated the time of its call and will host a conference call and audio webcast on Thursday, May 8, 2025, at 4:00 p.m. ET to discuss the Company’s financial results ...